Sangamo Therapeutics, Inc.’s Free Cash Flow Growth at a glance
Sangamo Therapeutics, Inc. reports free cash flow growth of 72.6% for Dec 2024. The prior period recorded -0.9% (Dec 2023). Year over year the metric moved +73.5 pts (+8,148.9%). The rolling three-period average stands at 25.6%. Data last refreshed Dec 7, 2025, 2:53 AM.
Latest reading
72.6% · Dec 2024
YoY movement
+73.5 pts (+8,148.9%)
Rolling average
25.6%
Current Free Cash Flow Growth
72.6%
+73.5 pts
+8,148.9%
Rolling average
25.6%
Latest Value
72.6%
Dec 2024
YoY Change
+73.5 pts
Absolute
YoY Change %
+8,148.9%
Rate of change
3-Period Avg
25.6%
Smoothed
Narrative signal
Sangamo Therapeutics, Inc.’s free cash flow growth stands at 72.6% for Dec 2024. Year-over-year, the metric shifted by +73.5 pts, translating into a +8,148.9% rate of change versus the prior period.
Pair this momentum with product cadence, pricing power, and capital allocation moves to understand durability.
Blend with balance sheet, cash flow, and peer benchmarks from AlphaPilot’s broader dashboards to shape an investable thesis.
How free cash flow growth shapes Sangamo Therapeutics, Inc.'s story
As of Dec 2024, Sangamo Therapeutics, Inc. reports free cash flow growth of 72.6%. Gauge reinvestment strength and capital return capacity using free cash flow growth over multiple reporting periods.
Cash flow versus earnings
Free cash flow growth can diverge from earnings due to working capital and capex swings. Track both to confirm quality.
Capital allocation insights
Rising free cash flow enables dividends, buybacks, and debt reduction—key levers for shareholder value.
Valuation Multiples
Compare how the market prices revenue, equity, and operating cash flow versus peers and history.
Profitability & Margins
Understand cost structure and capital efficiency trends across gross, operating, and net results.
Gross Margin
100%
Operating Margin
-179.9%
Net Profit Margin
-169.4%
Return on Equity
-430.1%
Return on Assets
-96.4%
Growth Momentum
Track whether top-line, earnings, and free cash flow growth are accelerating or cooling.
Balance Sheet Strength
Evaluate leverage, liquidity, and cash generation capacity that underpin resilience.
Shareholder Returns
Follow dividend sustainability and cash generation relative to market value.
Sangamo Therapeutics, Inc. (SGMO) FAQs
Answers tailored to Sangamo Therapeutics, Inc.’s free cash flow growth profile using the latest Financial Modeling Prep data.
What is Sangamo Therapeutics, Inc.'s current free cash flow growth?
As of Dec 2024, Sangamo Therapeutics, Inc. reports free cash flow growth of 72.6%. This reading reflects the latest filings and price data for SGMO.
How is Sangamo Therapeutics, Inc.'s free cash flow growth trending year over year?
Year-over-year, the figure shifts by +73.5 pts (+8,148.9%). Pair this context with revenue growth and free cash flow signals to gauge momentum for SGMO.
Why does free cash flow growth matter for Sangamo Therapeutics, Inc.?
Free cash flow growth measures how quickly operating cash surplus expands compared with the prior period. For Sangamo Therapeutics, Inc., operating within Healthcare — Biotechnology, tracking this metric helps benchmark management's execution against close competitors.
Is Sangamo Therapeutics, Inc.'s free cash flow growth above its recent average?
Sangamo Therapeutics, Inc.'s rolling three-period average sits at 25.6%. Comparing the latest reading of 72.6% to that baseline highlights whether momentum is building or fading for SGMO.
How frequently is Sangamo Therapeutics, Inc.'s free cash flow growth refreshed?
Data for SGMO was last refreshed on Dec 7, 2025, 2:53 AM and updates automatically every 24 hours, keeping your valuation inputs current.